Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information
RESEARCH PLATFORM FOR
THE MOON SHOTS PROGRAM
The Institute for Applied Cancer Science (IACS) is committed to apply our understanding of mechanisms driving tumor development and maintenance into the development of impactful small-molecule cancer drugs for our patients in need.
IACS is part of MD Anderson’s Therapeutics Discovery division, a unique group of clinicians, researchers and drug development experts working collaboratively to develop the next generation of targeted, immune- and cell-based therapies.
Embedded within the nation’s leading cancer center, the Therapeutics Discovery team leverages innovative academic science and clinical excellence to work with the bench at the bedside. Using this approach, IACS works closely with the Moon Shots® and platforms to advance new targeted therapies to patients quickly, safely and effectively.
Cancer drug discovery remains an inefficient process, with challenges and bottlenecks that slow the development of new therapies. IACS and the Therapeutics Discovery division are working to overcome those obstacles through a unique, patient-driven approach only possible within MD Anderson.
IACS is built around a highly experienced team of professional drug discovery and development scientists, working seamlessly with world-class physicians and scientists and an unparalleled proximity to the clinic. Their mission is to design new small-molecule drugs that answer our patient’s most pressing needs.
This therapeutics engine has integrated translational medicine capabilities, including expertise in cancer biology, medicinal chemistry, pharmacology, structural biology, computational chemistry, animal modeling, computational and systems biology. IACS has successfully advanced multiple novel medicines from concept to clinical trials and has a robust portfolio of candidates being driven aggressively toward the clinic to improve patients’ lives.
MD Anderson and Exscientia plc announced a strategic collaboration to align the drug development expertise of IACS with the patient-centric artificial intelligence (AI) capabilities of Exscientia to advance novel small-molecule therapies.
MD Anderson and Eisbach Bio GmbH announced a strategic research collaboration to discover and develop precision oncology drugs that target synthetic lethal engines key to tumor genome evolution. This collaboration will generate medicines that selectively disrupt genome replication and DNA repair in cancers harboring defined genetic alterations.
A novel targeted therapy, originally developed by the Therapeutics Discovery division, was licensed by BridgeBio Pharma, Inc. to Bristol Myers Squibb. This establishes opportunities for potentially developing and commercializing the drug as a best-in-class SHP2 inhibitor for treating cancer.
The glutaminase inhibitor IACS-6274, discovered and developed within Therapeutics Discovery, appears to be well-tolerated with successful target inhibition and early signs of anti-tumor activity in a biomarker-driven Phase I trial.
Learn moreThrough a patient-driven translational biology effort, Therapeutics Discovery researchers identified and validated asparagine synthetase as a candidate biomarker to predict patients with ovarian cancer likely to benefit from treatment with the metabolic inhibitor IACS-6274.
SHP2 Inhibitor Overcomes Therapeutic Resistance
New preclinical research from MD Anderson and Navire Pharma finds that the novel SHP2 inhibitor IACS-13909 is able to overcome multiple therapeutic-resistance mechanisms in non-small cell lung cancer, suggesting a possible new approach to treating cancers that have developed resistance to the targeted EGFR inhibitor osimertinib.
The Therapeutics Discovery division and Orionis Biosciences have
announced a research collaboration designed to unlock new drug
development opportunities. The project combines Orionis’
high-throughput drug discovery technologies with Therapeutics
Discovery’s expertise in small-molecule therapies and translational
biology.
